Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer
Sponsor: Breast International Group
Listed as NCT00553358, this PHASE3 trial focuses on Neoplasms, Breast and remains completed. Sponsored by Breast International Group, it has been updated 20 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
20 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 15 earlier versions
-
Sep 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Completed PHASE3
-
May 2021 — Jun 2021 [monthly]
Completed PHASE3
-
Mar 2021 — May 2021 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2020 — Oct 2020 [monthly]
Completed PHASE3
-
Mar 2020 — Jun 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Breast International Group
- Novartis Pharmaceuticals
- SOLTI Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athlone Park, Amanzimtoti, South Africa , Bangalore, India , Barcelona, Spain , Bayonne, France , Berazategui, Argentina , Berlin, Germany , Bordeaux, France , Bournemouth, United Kingdom , Brno, Czechia , Brussels, Belgium and 92 more locations